Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NURO Friday 2 more form 4 buys. https://ih.advfn.com/p.php?pid=nmona&article=76262138&symbol=NURO
NURO two Form 4 buys after hours.
2 form 4 buys ah.
At this point that will work!
Hope it is for at least 1.27. That's what I need to break even.
XGTI new form 4 buy. https://ih.advfn.com/p.php?pid=nmona&article=76213950&symbol=XGTI
XPLR. As of the close of business on October 23, 2017, the record date for the Annual Meeting, there were 11,020,905 shares of the Company’s common stock issued and outstanding and entitled to vote at the Annual Meeting.
NURO. NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle.
"We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is correlated with better results. The technology in this patent helps Quell meet the needs of even the most active users,” said Shai N. Gozani, M.D., Ph.D.
About Quell
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a clinical study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
XGTI.
xG Technology Awarded Contract to Provide Interference Mitigation Technology under Government Shared Spectrum Research Progra...
Print
Alert
XG Technology, Inc. (NASDAQ:XGTI)
Intraday Stock Chart
Today : Wednesday 29 November 2017
Click Here for more XG Technology, Inc. Charts.
SARASOTA, Fla., Nov. 29, 2017 /PRNewswire/ -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a leading provider of wireless video solutions to broadcast, law enforcement and defense markets, and private mobile broadband networks for critical communications, announced that it has been awarded a subcontract from Leidos to provide interference mitigation solutions and simulation models under a Defense Advanced Research Projects Agency (DARPA) shared spectrum research program.
The award leverages xG Technology's innovations in software defined cognitive radio (SDCR) platforms, and expertise in developing architectures that better enable spectrum sharing and significantly enhance interference mitigation.
The program seeks to develop spectrum sharing technologies that enable access and mitigate the impact of spectrum congestion. This congestion is a growing problem and limits operational capabilities due to the increasing bandwidth demands for wireless communications, the use of net-centric and unmanned systems, and the need for increased flexibility in communications.
"xG's contributions to this program in the area of interference mitigation reflect xG's growing capabilities in supporting government programs in this area," said John Coleman, President of xG's Federal Business Unit. "Our support of this program reflects our leading position in interference mitigation, spectrum sharing technologies, and high reliability communications systems and associated research."
XGTI.
xG Technology Awarded Contract to Provide Interference Mitigation Technology under Government Shared Spectrum Research Progra...
Print
Alert
XG Technology, Inc. (NASDAQ:XGTI)
Intraday Stock Chart
Today : Wednesday 29 November 2017
Click Here for more XG Technology, Inc. Charts.
SARASOTA, Fla., Nov. 29, 2017 /PRNewswire/ -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a leading provider of wireless video solutions to broadcast, law enforcement and defense markets, and private mobile broadband networks for critical communications, announced that it has been awarded a subcontract from Leidos to provide interference mitigation solutions and simulation models under a Defense Advanced Research Projects Agency (DARPA) shared spectrum research program.
The award leverages xG Technology's innovations in software defined cognitive radio (SDCR) platforms, and expertise in developing architectures that better enable spectrum sharing and significantly enhance interference mitigation.
The program seeks to develop spectrum sharing technologies that enable access and mitigate the impact of spectrum congestion. This congestion is a growing problem and limits operational capabilities due to the increasing bandwidth demands for wireless communications, the use of net-centric and unmanned systems, and the need for increased flexibility in communications.
"xG's contributions to this program in the area of interference mitigation reflect xG's growing capabilities in supporting government programs in this area," said John Coleman, President of xG's Federal Business Unit. "Our support of this program reflects our leading position in interference mitigation, spectrum sharing technologies, and high reliability communications systems and associated research."
XPLR.
Louisiana Department of Environmental Quality Inspectors Go Fully Paperless with Xplore’s HazLoc-Certified Rugged Tablets
Xplore Technologies Corp. (NASDAQ:XPLR) today announced that inspectors with the Louisiana Department of Environmental Quality (DEQ) are now using the Xplore XSLATE B10 fully rugged tablets as their primary workstation in the office, vehicle and field. The State agency wanted to transition its field team to a fully paperless operating environment, and Xplore’s C1D2-certified Windows® tablets were the only mobile computers in their class that could safely be used in vehicle as well as in-hand at inspection sites where combustible gasses and flames are present.
Louisiana’s state inspectors are responsible for routinely monitoring gas stations, refineries, chemical plants, underground wells, landfills and other sites where environmental quality protections are mandated. They are also dispatched to ‘ground zero’ after fires, spills and other emergencies where there’s often an elevated presence of hazardous material.
“Knowing there is an inherent risk with bringing electronic devices around volatile substances, we have to ensure that any mobile device we give them meets strict Hazardous Location use standards,” explained Jason Hanchey, business analytics specialist, Office of Management and Finance, State of Louisiana. “We feel very comfortable sending them into the field with the XSLATE B10 rugged tablet given its intrinsic safety features. Plus, the tablet makes it much easier to examine infrastructure integrity and air, ground, and water quality in time-sensitive situations.”
The Louisiana DEQ is using the XSLATE B10 rugged tablets to immediately collect results from soil sample, groundwater, radiation level and plant stack tests using digitally fillable versions of its standard inspection forms. Inspectors then submit the findings to the site representative, as well as the department’s back-office system for official recording, in real-time. This eliminates the risk of lost reports, transcription errors and remediation delays.
“Our inspectors are notorious for their messy handwriting, and there were many times where they could not read what they had written on the carbon-copy inspection report when they got back to the office,” Hanchey continued. “That is no longer a problem thanks to the easy data inputs and expedited report submissions facilitated by the Xplore rugged tablet.”
The Intel®-powered XSLATE B10 and Office Dock combination also provide the ideal desktop configuration for these inspectors when they were in the office. This has allowed the Department of Environmental Quality to standardize on a single PC platform for all job sites without compromising on computing capabilities. The rugged tablet meets the State’s very strict security, performance and connectivity criteria, which is critical considering all highly sensitive data related to inspection activities is now being captured and recorded via electronic methods only.
“Louisiana’s inspectors spend their days executing a comprehensive environmental fortification program that protects the public’s health, safety and welfare,” commented John Graff, vice president of marketing at Xplore. “That is why we worked closely with the DEQ to ensure our rugged tablet-based solutions provide both a reliable computing platform and a scalable solution to support their growing inspection demands.”
For more information about the XSLATE B10 fully rugged tablet, please visit www.xploretech.com/XSLATEB10. To learn about Xplore’s mobility solutions for government organizations, visit www.xploretech.com/government. Additional guidance about the safe use of mobile computers in Hazardous Locations can be found at www.xploretech.com/HazLoc.
ZIOP. Go to the ZIOP board on IV.
ZIOP huge short interest and fake rumors of something bad coming out if the conference call today. They present at next months ASH conference also.
Xgti additional news. https://ih.advfn.com/p.php?pid=nmona&article=76131995&symbol=XGTI
ZIOP from SNO 2017. News on the 1st abstract
None of the 4 patients in low dose has died and the one in the mid steroid group is alive at 11 months.
The 4 low dose are alive at 9.5, 10, 11 and 23.5 months. That is proof that IL-12 is working.
Very important news. The 12.5 months survival ignores the 4 patients alive at less than 12.5 months. The 4 are at 9.5 to 11 months. So the survival will be more than 12.5 months my Jan 2018 and it is impossible to know how much higher it will go.
The low dose could be over 12.5 months before one of the 4 die. Amazing to imagine what the survival data will look like when the trial ends.
This all bores well for phase 3.
http://www.ziopharm.com/content/02-pipeline/03-presentations-publications/1-22nd-annual-meeting-and
-education-day-of-the-society-for-neuro-oncology-sno-in-san-francisco/2-phase-1-study-of-ad-rts-hil-
12-veledimex-in-adult-recurrent-glioblastoma/2017sno_chiocca_ph1studyad-rts-hil-12veladultrgbm.pdf
Awesome news on the 1st abstract
None of the 4 patients in low dose has died and the one in the mid steroid group is alive at 11 months.
The 4 low dose are alive at 9.5, 10, 11 and 23.5 months. That is proof that IL-12 is working.
Very important news. The 12.5 months survival ignores the 4 patients alive at less than 12.5 months. The 4 are at 9.5 to 11 months. So the survival will be more than 12.5 months my Jan 2018 and it is impossible to know how much higher it will go.
The low dose could be over 12.5 months before one of the 4 die. Amazing to imagine what the survival data will look like when the trial ends.
This all bores well for phase 3.
http://www.ziopharm.com/content/02-pipeline/03-presentations-publications/1-22nd-annual-meeting-and
-education-day-of-the-society-for-neuro-oncology-sno-in-san-francisco/2-phase-1-study-of-ad-rts-hil-
12-veledimex-in-adult-recurrent-glioblastoma/2017sno_chiocca_ph1studyad-rts-hil-12veladultrgbm.pdf
ZIOP presenting at SNO this weekend.
AdRTShIL12 Plus Veledimex Presentations at SNO 2017 Poster Oral Presentation Oral PresentationPhase 1 Study of Ad RTShIL Veledimex12 plus in Pediatric Brain Tumors Stewart Goldman Lurie Children’s HospitalA Phase 1 study of Ad RTShIL veledimex , M.D., 12 + in adult recurrent glioblastoma Antonio Chiocca , M.D., Ph.D., Brigham and Women’s / Dana Cancer CenterFarber Controlled Expression of IL 12 Improves Survival in Glioma by Activating the Immune Response in Mice and Humans John A. Barrett , ZIOPHARM Conference call following SNO. Details to follow Ph.D., Oral Presentation Controlled Local Expression of IL12 as Gene Therapy Concomitant with Systemic Chemotherapy Improves Survival in Glioma John A. Barrett ZIOPHARM , Ph.D., Third Quarter 2017 Financial Results and Updates on Recent Activities
XGTI. Integrated Microwave Technology LLC,* Hackettstown, New Jersey, has been awarded a $12,583,035 firm-fixed-price, foreign military sales (Afghanistan) contract for the purchase of hand-held intelligence, surveillance and reconnaissance receiver devices. Bids were solicited via the Internet with eight bids received. Work locations and funding will be determined with each order, with an estimated completion date of Sept. 24, 2020. The 408th Contracting Support Brigade, Regional Contracting Center, Qatar, is the contracting activity (W912D2-18-D-5000).
2016
https://www.prnewswire.com/news-releases/xg-technology-completes-purchase-of-integrated-microwave-technologies-llc-300212653.html
XGTI. Integrated Microwave Technology LLC,* Hackettstown, New Jersey, has been awarded a $12,583,035 firm-fixed-price, foreign military sales (Afghanistan) contract for the purchase of hand-held intelligence, surveillance and reconnaissance receiver devices. Bids were solicited via the Internet with eight bids received. Work locations and funding will be determined with each order, with an estimated completion date of Sept. 24, 2020. The 408th Contracting Support Brigade, Regional Contracting Center, Qatar, is the contracting activity (W912D2-18-D-5000).
2016
https://www.prnewswire.com/news-releases/xg-technology-completes-purchase-of-integrated-microwave-technologies-llc-300212653.html
XGTI. Integrated Microwave Technology LLC,* Hackettstown, New Jersey, has been awarded a $12,583,035 firm-fixed-price, foreign military sales (Afghanistan) contract for the purchase of hand-held intelligence, surveillance and reconnaissance receiver devices. Bids were solicited via the Internet with eight bids received. Work locations and funding will be determined with each order, with an estimated completion date of Sept. 24, 2020. The 408th Contracting Support Brigade, Regional Contracting Center, Qatar, is the contracting activity (W912D2-18-D-5000).
2016
https://www.prnewswire.com/news-releases/xg-technology-completes-purchase-of-integrated-microwave-technologies-llc-300212653.html
CEO interview. https://vimeo.com/212099893
SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into entered into a Warrant Exercise Agreement with certain holders of outstanding warrants to purchase up to an aggregate of 5,509,642 shares of the Company's common stock, at its stated exercise price of $1.69 per share. Although each holder agreed to exercise, from time-to-time and in accordance with the terms of the warrants, the holders exercised all of the warrants held by it for cash today.
As a result, the Company received gross proceeds of approximately $9.3 million from the exercise of the warrants. The Company expects to use the proceeds for working capital and general corporate purposes, including primarily for its PISCES/KEYNOTE-695 clinical trial and for other clinical and research and development activities.